"Dr. Suarez has been one of the most committed long term supporters of focused ultrasound ablation in the U.S..." - Dr. Mark Carol
Charlotte, NC (PRWEB) April 13, 2016
SonaCare Medical, LLC announces that Sonablate HIFU prostate ablation is now available in Miami, Florida. Dr. George Suarez launched his U.S.-based HIFU program in late February out of the Miami Sunset Surgery Center, and performed a remarkable ten cases during the first two weeks of offering this alternative prostate care option.
Dr. Suarez has been an avid HIFU ablation advocate for many years. Having a long-term relationship with SonaCare Medical, he is one of few physicians to have personally witnessed the evolution of the device over the past 10+ years.
“Having had the opportunity to perform HIFU procedures outside the U.S. for over a decade prior to FDA authorization has provided me invaluable experience and knowledge," said Dr. George Suarez, a board-certified urologist. "That kind of experience allows me to perform multiple procedures per week that yield results for patients who seek a quick and efficient outpatient procedure. HIFU is a prostate care option that delivers outcomes equivalent to existing prostate procedures, but more importantly, it does so with a significantly reduced risk of side effects.” Dr. Suarez adds, “It is all about finding an alternative option that will allow men to preserve their quality of life, life-style, and dignity post-procedure.”
SonaCare Medical's Chief Executive Officer, Dr. Mark Carol, comments, “Dr. Suarez has been one of the most committed long term supporters of focused ultrasound ablation in the U.S. George was one of the original founders of International HIFU, the predecessor of SonaCare Medical, and he has treated hundreds of patients over the years at multiple locations outside the United States. I am personally delighted that George now has the opportunity to bring his extensive experience with Sonablate to bear in southern Miami, where I am sure he will continue to further the development of prostate ablation using Sonablate as a robust clinical tool.” Thomas Mendell, SonaCare Medical’s Chairman of the Board, states additionally, “George was a valued member of our board who brought a practicing-doctor's perspective and a sense of humor to our board meetings, which was especially valuable in the early days of the Company. It is rewarding to know he will be continuing his work with Sonablate technology.”
Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.
For additional information, visit http://www.SonaCareMedical.com
SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com
Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.